EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma

Fumihiro Ito iD, Koki Kobayashi, Gaku Hayashi, Shunsuke Kamijo, Takashi Fujita

IJU Case Reports · 2026-03 · 9 (2)

DOI: 10.1002/iju5.70160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 08.03.2026. Verfasst von Fumihiro Ito und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Avelumab maintenance after response to platinum chemotherapy improves outcomes in metastatic urothelial carcinoma. Progression during maintenance presents a therapeutic dilemma. Case Presentation A 72‐year‐old man underwent radical cystectomy and left nephroureterectomy for high‐grade urothelial carcinoma. Two and a half years later, a solitary pelvic nodal recurrence achieved complete response to gemcitabine–cisplatin, after which avelumab maintenance was started. After 16 cycles, the same node regrew, indicating progression. Pembrolizumab was initiated and induced a second complete response after four cycles. He remains recurrence‐free for three years without immune‐related adverse events.

Conclusion

Durable remission with pembrolizumab following progression on avelumab suggests that switching from PD‐L1 to PD‐1 blockade can overcome resistance in selected patients; prospective studies and biomarker strategies, including PD‐L2 assessment, are warranted and may guide individualized rechallenge strategies.

Schlagwörter

Stichwörter der Autor:innen

avelumabmaintenance therapypembrolizumabrechallengeurothelial carcinoma

Autor:innen und Institutionen

  • Department of Urology Gifu Prefectural Tajimi Hospital Tajimi Japan.

ORCID-Profile: Fumihiro Ito

Zitieren

APA

Ito, F., Kobayashi, K., Hayashi, G., Kamijo, S., & Fujita, T. (2026). Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma. IJU Case Reports, 9(2). https://doi.org/10.1002/iju5.70160

Vancouver

Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T. Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma. IJU Case Reports. 2026;9(2). doi:10.1002/iju5.70160

BibTeX
@article{Ito2026,
  author = {Ito, Fumihiro and Kobayashi, Koki and Hayashi, Gaku and Kamijo, Shunsuke and Fujita, Takashi},
  title = {Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {2},
  doi = {10.1002/iju5.70160}
}
Kostenlos starten →